Lifarizine

Drug Profile

Lifarizine

Alternative Names: RS 87476

Latest Information Update: 12 Jan 2001

Price : $50

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Roche Palo Alto
  • Class Anti-ischaemics; Imidazoles; Nootropics; Piperazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Stroke

Most Recent Events

  • 12 Jan 2001 Profile reviewed but no significant changes made
  • 26 Feb 1997 Suspended-II for Stroke in USA (Unknown route)
  • 16 Oct 1996 A clinical study has been added to the Therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top